Share Twitter LinkedIn Facebook Email Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses Two Trials looking at Inhibitors in 1st-line Therapy Combinations, Cediranib & Olapanib, and Bevacizumab & Olapanib.
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Acute Lymphoblastic Leukemia 3 Mins Read
FDA Approves Inotuzumab Ozogamicin (BESPONSA) for Acute Lymphoblastic Leukemia in Pediatric Patients [Exclusive Video] Acute Lymphoblastic Leukemia 3 Mins Read
Spotlight on CAR T-cell Therapy in 2024: Advances & Clinical Insights Acute Lymphoblastic Leukemia 3 Mins Read